Can neural tube defects be detected on a 10‑week ultrasound scan?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Detection of Neural Tube Defects at 10 Weeks Gestation

Neural tube defects cannot be reliably detected on a routine 10-week ultrasound scan, as standard screening for these anomalies is optimally performed between 16-20 weeks gestation using a combination of second-trimester anatomic ultrasound and maternal serum alpha-fetoprotein (MSAFP) screening. 1, 2

Timing of Neural Tube Defect Screening

Standard Screening Window

  • The optimal time for NTD screening is 16-18 weeks gestation using MSAFP, which can detect 75-90% of open neural tube defects and 95% of anencephaly cases. 1, 2, 3

  • The standard fetal anatomic ultrasound examination is recommended between 18-20 weeks gestation, when cranial signs of spina bifida (lemon-shaped head, banana cerebellum, ventriculomegaly) become reliably visible. 1, 2

  • Testing can be performed between 15-20.9 weeks, but accuracy decreases outside the optimal 16-18 week window. 1

Why 10 Weeks Is Too Early

  • At 10 weeks gestation, the neural tube has only recently closed (closure occurs by approximately 4 weeks post-conception), and the characteristic ultrasound findings used to diagnose NTDs have not yet developed. 1

  • The cranial signs that allow indirect detection of spina bifida (lemon sign, banana sign) are not reliably present until the second trimester. 4, 5

Limited First-Trimester Detection Capabilities

Severe Defects Only

  • Anencephaly may occasionally be detected as early as 10-12 weeks if the defect is severe, as the absence of cranial vault can sometimes be visualized. 6, 7

  • Some research reports describe detection of open spina bifida at 10-11 weeks using specialized techniques, but these are case reports, not standard practice. 6

Emerging Research Markers (Not Standard of Care)

  • Intracranial translucency (IT) has been studied as a potential first-trimester marker, with absence of IT associated with later diagnosis of NTDs, but this remains investigational and is not part of routine screening protocols. 8

  • Transvaginal ultrasound between 12-17 weeks can detect cranial signs (banana sign, cerebellar abnormalities) in some cases, but this is earlier than standard screening and requires specialized expertise. 4

Recommended Screening Algorithm

First Trimester (11-14 weeks)

  • Perform combined first-trimester screening (nuchal translucency + PAPP-A + β-hCG) for chromosomal abnormalities, which does NOT screen for neural tube defects. 1, 9

  • If nuchal translucency is ≥3.5 mm, this warrants detailed anatomic ultrasound and fetal echocardiogram even though it is not specific for NTDs. 1, 9

Second Trimester (16-20 weeks)

  • All women who had first-trimester screening should be offered MSAFP screening between 16-18 weeks specifically for neural tube defect detection. 1, 2, 9

  • Perform comprehensive anatomic ultrasound at 18-20 weeks to directly visualize the spine and assess for cranial signs of spina bifida. 1, 2

  • MSAFP cut-off levels of 2.0-2.5 MoM in singleton pregnancies indicate elevated risk requiring follow-up. 1, 3

Follow-Up for Elevated MSAFP

  • Genetic counseling, targeted ultrasound examination, and amniocentesis (measuring amniotic fluid AFP and acetylcholinesterase) are recommended when MSAFP is elevated. 1, 3

  • Combined amniotic fluid AFP (≥2.0 MoM) and acetylcholinesterase testing achieves 97% detection rate for open spina bifida with only 0.1% false-positive rate. 3

Critical Pitfalls to Avoid

  • Do not rely on 10-week ultrasound to exclude neural tube defects, as the sensitivity is extremely poor and most defects will be missed. 1, 2

  • Ensure accurate gestational age dating, as AFP values change 13-15% per week between 15-22 weeks, and a 2-week error requires complete reinterpretation. 1, 3

  • Do not skip second-trimester MSAFP screening in women who had first-trimester combined screening, as first-trimester screening does not detect neural tube defects. 1, 9

  • Adjust MSAFP interpretation for maternal weight, race (values are higher in Black/African American women), insulin-dependent diabetes, and number of fetuses. 1, 3

Special Populations Requiring Enhanced Surveillance

  • Obese women should have anatomic surveys at 20-22 weeks (2 weeks later than standard) due to decreased visualization, with repeat ultrasound in 2-4 weeks if incomplete. 1

  • Women with previous NTD-affected pregnancy or family history require higher-dose folic acid supplementation (not just screening modifications). 1

  • Fetal MRI can be performed at or after 22 weeks when ultrasound findings are incomplete or require additional anatomic detail. 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Second Trimester Ultrasound Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Causes of Elevated Maternal Serum Alpha-Fetoprotein (MSAFP)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

The early diagnosis of neural tube defects.

Prenatal diagnosis, 1993

Research

Prenatal diagnosis of neural tube defect before 12 weeks' gestation: direct and indirect ultrasonographic semeiology.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 1997

Guideline

First‑Trimester Combined Screening for Fetal Aneuploidy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.